Summary
Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K on May 1, 2025, announcing its financial results for the quarter ended March 31, 2025. While the 8-K itself primarily serves as a notification of the release and doesn't contain the detailed financial data, it references a press release (Exhibit 99.1) which holds the crucial operational and financial condition information for investors. This filing indicates that key performance metrics, revenue figures, and any significant updates on the company's pipeline or commercial performance for the first quarter of 2025 were disclosed in the accompanying press release.
Key Highlights
- 1Alnylam Pharmaceuticals announced its Q1 2025 financial results on May 1, 2025, via an 8-K filing.
- 2The 8-K filing references a press release (Exhibit 99.1) containing the detailed financial and operational results for the quarter ended March 31, 2025.
- 3Investors should refer to the furnished press release for specific financial metrics, revenue figures, and operational updates.
- 4The filing confirms adherence to SEC reporting requirements for timely disclosure of quarterly results.
- 5Information contained in Item 2.02 and Exhibit 99.1 is furnished, not filed, meaning it's not subject to specific liability provisions of the Exchange Act unless incorporated by reference.
- 6The Cover Page Interactive Data File is also provided as an exhibit.
Frequently Asked Questions
The detailed financial results are located in the press release furnished as Exhibit 99.1 to this 8-K filing, dated May 1, 2025. This document contains the specific financial performance and operational updates.
This 8-K filing does not contain the specific financial performance indicators. Investors need to consult the furnished press release (Exhibit 99.1) which was issued on May 1, 2025, for details on revenue, earnings, and other financial metrics.
The 8-K filing itself primarily announces the results and directs investors to the press release. The press release (Exhibit 99.1) would typically contain any forward-looking statements or financial guidance provided by the company for future periods.
When information is 'furnished' under Item 2.02, it is made available to the public but is not subject to the same legal liabilities under Section 18 of the Exchange Act as 'filed' information, unless the company specifically incorporates it into a filing under the Securities Act of 1933 or the Exchange Act.